文献速递骨软组织肉瘤与黑色素瘤

立体定向放射外科系统控制脑转移后靶向与免疫治疗黑色素瘤的生存

Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
PubMed 文献 · Eur J Cancer · 2017-08-04

回顾性队列纳入2010至2015年179例转移性黑色素瘤脑转移患者,首次脑转移均接受伽玛刀治疗。其中109例在首次伽玛刀后接受免疫治疗和/或靶向治疗,中位OSGK1为10.95个月,1年和2年生存率分别为49.5%和27.4%,未接受免疫或靶向治疗者中位OS为2.29个月(P<.001)。

要点

  • 首次伽玛刀后接受免疫和/或靶向治疗者中位OSGK1为10.95个月,1年生存率49.5%,2年生存率27.4%。
  • 未接受免疫或靶向治疗者中位OS为2.29个月(P<.001)。
  • BRAF野生型接受抗PD1或BRAF突变型接受BRAF抑制剂联合抗PD1者OSGK1最佳。

核心结论

  • 在真实世界脑转移黑色素瘤患者中,以伽玛刀控制脑转移联合靶向和/或免疫治疗的策略似乎实现了前所未有的生存率。

研究设计与样本

  • 回顾性队列研究,纳入2010年至2015年连续179例转移性黑色素瘤脑转移患者,首次脑转移均系统接受伽玛刀治疗,出现新脑转移时再次伽玛刀治疗。
  • 179例中109例在首次伽玛刀后接受免疫治疗和/或靶向治疗。
  • 研究时期为伊匹木单抗、BRAF±MEK抑制剂和抗PD1开始进入临床实践的时期。

主要发现

  • 接受免疫和/或靶向治疗者中位OSGK1为10.95个月,1年和2年生存率分别为49.5%和27.4%;未接受免疫或靶向治疗者中位OS为2.29个月(P<.001)。
  • 初始为单个脑转移者中位OS为14.46个月,1年和2年生存率分别为66.7%和43.4%。
  • 初始为2-3个脑转移者中位OS为8.85个月,1年和2年生存率分别为46.4%和31%。
  • 初始为>3个脑转移者中位OS为7.25个月,1年和2年生存率分别为37.2%和11.9%。
  • 多因素分析证实免疫治疗和靶向治疗对OSGK1具有显著且高度保护作用;BRAF野生型接受抗PD1者OSGK1为12.26个月,BRAF突变型接受BRAF抑制剂联合抗PD1者OSGK1为14.82个月。

关键数值与推荐

  • 接受免疫和/或靶向治疗者中位OSGK1为10.95个月,1年生存率49.5%,2年生存率27.4%;未接受者中位OS为2.29个月(P<.001)。
  • 初始单个脑转移者中位OS为14.46个月,1年和2年生存率分别为66.7%和43.4%。
  • 初始2-3个脑转移者中位OS为8.85个月,1年和2年生存率分别为46.4%和31%。
  • 初始>3个脑转移者中位OS为7.25个月,1年和2年生存率分别为37.2%和11.9%。
  • BRAF野生型接受抗PD1者OSGK1为12.26个月;BRAF突变型接受BRAF抑制剂联合抗PD1者OSGK1为14.82个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Targeted therapy (TT) and immunotherapies (ITs) have dramatically improved survival in metastatic melanoma (MM). However, their efficacy on brain metastasis (BM) remains limited and poorly documented. PATIENTS AND METHODS: Retrospective cohort of consecutive MM patients (pts) with BMs, all systematically upfront treated by Gamma-Knife (GK) at first BM and retreated in case of new BMs, from 2010 to 2015 at the time when ipilimumab BRAF ± MEK inhibitors and anti-PD1 were introduced in practice. Survival after 1st GK (OSGK1) according to prognostic factors and treatment. RESULTS: Among 179 consecutive pts treated by GK, 109 received IT and/or TT after the 1st GK. Median OSGK1 was 10.95 months and 1- and 2-year survival rates were 49.5% and 27.4%, respectively, versus a median overall survival (OS) of 2.29 months (p < .001) in those who did not receive IT or TT. In pts who initially had a single BM, median OS and 1- and 2-year survival rates were 14.46 months, 66.7% and 43.4%, respectively; in pts with 2-3 BMs: 8.85 months, 46.4% and 31%, respectively; in pts with >3 BMs: 7.25 months, 37.2% and 11.9%, respectively. Multivariate analysis for OSGK1 confirmed that IT and TT were significantly and highly protective. Best OSGK1 was observed in BRAF-wild-type pts receiving anti-PD1 or in BRAF-mutated pts receiving BRAF-inhibitors and anti-PD1 (12.26 and 14.82 months, respectively). CONCLUSION: In real-life MM pts with BMs, a strategy aiming at controlling BM with GK together with TT and/or TT seems to achieve unprecedented survival rates.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gaudy-Marqueste C, Dussouil AS, Carron R, et al. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. Eur J Cancer. 2017. PMID: 28783540. doi:10.1016/j.ejca.2017.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。